Advanced imaging techniques visualize macrophages in brain tumors in mouse models of glioblastoma.
PTEN deficiency drives an increased expression of LOX. LOX attracts macrophages which protect gliobastoma brain cancer cells and provide growth factor support for the tumor, a new mouse study reveals.
Combining an antibiotic drug that targets glutamine with the ketogenic diet helps kill glioblastoma cancer cells, reversing symptoms of the disease and improving survivability in mouse models.
A new vaccine for glioblastoma brain cancer suspends tumor growth and is well tolerated by patients, according to the results of an early phase clinical trial.
Researchers report administering immunotherapy treatment prior to surgery for those with recurring glioblastoma brain cancer is more effective that using the treatment after surgery.
Researchers have developed a new approach that uses microRNA in combination with chemotherapy to help treat glioblastoma brain cancer. In preclinical models, the approach increases survival of the deadly brain cancer five fold.
Researchers report our gender can determine longevity and response to treatment for glioblastoma brain cancer. The study reports male survival is determined by genes that control cell division, where as female survival is often determine by genes that regulate the ability of cancer cells to migrate to different brain areas.
A new study reveals distinct molecular differences in signatures of glioblastoma brain cancer between men and women. Researchers report current treatments for the brain cancer are more effective in women than in men. The findings could help to tailor treatments aimed at the different sexes and improve survival.
Researchers detail the use of a drug that may help block the way glioblastoma brain cancer cells respond to fluid flow. The finding could lead to stopping glioblastoma from spreading.
A new study reports a genetically modified poliovirus therapy has been shown to improve long term survival rates in recurrent glioblastoma brain cancer patients. Researchers say the therapy had a three year survival rate for 21 percent of participants in a phase 1 clinical trial, compared to just 4% of patients who received more standard treatments.
A new brain cancer atlas maps out comprehensive, visually rich information about the anatomical and genetic bases of glioblastoma, researchers report.
A new study in PNAS reports blocking the expression of MDA-9/Syntenin forces glioma stem cells to lose their ability to induce protective autophagy.
